Get Cash Back and $0 Commissions
+ The Power of TradeStation

ATTENTION MRNS INVESTORS: Contact Berger Montague About a Marinus Pharmaceuticals Class Action Lawsuit

Newsfile 10-Jun-2024 12:07 PM

Philadelphia, Pennsylvania--(Newsfile Corp. - June 10, 2024) - A securities fraud lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ:MRNS). The lawsuit is captioned Bishins v. Marinus Pharmaceuticals, Inc., et al., No. 2:24-cv-02430 (E.D. Pa.), and is filed on behalf of purchasers of Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").


Investors who purchased or acquired Marinus securities during the Class Period may, no later than August 5, 2024, seek to be appointed as a lead plaintiff representative of the class.

Marinus describes itself as a "commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone)." The Randomized Therapy in Status Epilepticus ("RAISE") trial, is a "pivotal Phase 3 trial in refractory status epilepticus (RSE) patients."

According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) they had understated the risk of failure to meet the early-stopping criteria in the RAISE trial; and (2) a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial.

For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at or (267) 637-3176, or Andrew Abramowitz at or (215) 875-3015, or CLICK HERE.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

James Maro, Senior Counsel
Berger Montague
(267) 637-3176

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015

To view the source version of this press release, please visit

Image for Press Release 1913561